• CAT Number: I004263
  • CAS Number: 667463-85-6
  • Molecular Formula: C18H12BrN3O3
  • Molecular Weight: 398.22
  • Purity: ≥95%
Inquiry Now

BIO-acetoxime(Cat No.: I004263), is a powerful dual inhibitor targeting both GSK3α and GSK3β with impressive potency, characterized by an IC50 of 10 nM. What sets BIO-acetoxime apart is its remarkable selectivity, demonstrating over 240-fold specificity when compared to CDK5/p25, CDK2/cyclin A, and CDK1/cyclin B. This selectivity is particularly advantageous for research focusing on GSK3-related cellular processes, such as cell signaling and regulation. If you require additional information or assistance regarding BIO-ketoxime, please feel free to contact us.

Catalog Number I004263
CAS Number 667463-85-6

BIO-acetoxime; (2′Z,3′E)-6-Bromoindirubin-3′-acetoxime, 6-Bromoindirubin acetoxime, 6-Bromoindirubin-3′-acetoxime, BIA;(2Z,3E)-3-(acetoxyimino)-6/’-bromo-[2,3/’-biindolinylidene]-2/’-one

Molecular Formula


Purity 95%
Target GSK-3a/b inhibitor
Solubility Soluble in DMSO, not in water
Storage 2-8°C
IUPAC Name [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate
InChI InChI=1S/C18H12BrN3O3/c1-9(23)25-22-16-12-4-2-3-5-13(12)20-17(16)15-11-7-6-10(19)8-14(11)21-18(15)24/h2-8,21,24H,1H3/b22-16+

1:Arch Virol. 2013 Jun;158(6):1287-96. doi: 10.1007/s00705-013-1629-3. Epub 2013 Feb 8. Antiherpetic potential of 6-bromoindirubin-3/’-acetoxime (BIO-acetoxime) in human oral epithelial cells.Hsu MJ,Hung SL, PMID: 23392633 DOI: 10.1007/s00705-013-1629-3 </br><span>Abstract:</span> Glycogen synthase kinase 3 (GSK-3) functions in the regulation of glycogen metabolism, in the cell cycle, and in immune responses and is targeted by some viruses to favor the viral life cycle. Inhibition of GSK-3 by 6-bromoindirubin-3/’-acetoxime (BIO-acetoxime), a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, protects cells from varicella infection. In this study, we examined the effects of BIO-acetoxime against herpes simplex virus-1 (HSV-1) infection in human oral epithelial cells, which represent a natural target cell type. The results revealed that BIO-acetoxime relieves HSV-1-induced cytopathic effects and apoptosis. We also found that BIO-acetoxime reduced viral yields and the expression of different classes of viral proteins. Furthermore, addition of BIO-acetoxime before, simultaneously with or after HSV-1 infection significantly reduced viral yields. Collectively, BIO-acetoxime may suppress viral gene expression and protect oral epithelial cells from HSV-1 infection. These results suggest the possible involvement of GSK-3 in HSV-1 infection.

Request a Quote